Emilien BILLON

Mr. Emilien BILLON


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2018 in European Journal of Cancer
Verified
Journal Article
Closed access
GGGwenaëlle Gravis
Gwenaëlle Gravis
EBEmilien BILLON
Emilien BILLON
CBCapucine Baldini
Capucine Baldini
CMChristophe Massard
Christophe Massard
WHWerner Hilgers
Werner Hilgers
YLYohann Loriot
Yohann Loriot

31 January 2025 in Cancer Immunology Research
Verified
Journal Article
Closed access
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MPMarylou Panouillot
Marylou Panouillot
MRMarie-Sarah Rouvière
Marie-Sarah Rouvière
EBEmilien BILLON
Emilien BILLON
SFStéphane Fattori
Stéphane Fattori
DODaniel Olive
Daniel Olive
Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis in patients with cancer. We evaluated the cervical tumor immune microenvironment, specifically focusing on TLS, using combined high-throughput phenotyping, soluble factor concentration dosage in the tumor microenvironment, and spatial interaction analyses. We found that TLS presence was associated with a more inflammatory soluble microenvironment, with the presence of B cells as well as more activated macrophages and dendritic cells (DC). Furthermore, this myeloid cell activation was associated with the expression of immune checkpoints, such as PD-L1 and CD40, and the proximity of activated conventional type 2 DCs to CD8+ T cells, indicating better immune interactions and tumor control. Finally, we associated TLS presence, greater B-cell density, and activated DC density with improved progression-free survival, substantiating TLS presence as a potential prognostic marker. Our results provide evidence that TLS presence denotes cell activation and immunotherapy target expression.

11 June 2018 in Clinical Sarcoma Research
Verified
Journal Article
Open access
PDF file
EBEmilien BILLON
Emilien BILLON
ASAnne-Marie Stoppa
Anne-Marie Stoppa
LMLena Mescam
Lena Mescam
MBMassimo Bocci
Massimo Bocci
AMAudrey Monneur
Audrey Monneur
FBFrançois Bertucci
François Bertucci
Kaposi’s sarcoma is a low-grade mesenchymal angioproliferative tumor, most commonly observed in immunocompromised individuals, such as HIV-infected patients. Iatrogenic Kaposi’s sarcoma occurs in patients undergoing immunosuppressive therapies. Rituximab is a chimeric monoclonal antibody targeted against the pan B cell marker CD20. Because of its immunosuppressive effects through reduction of mature B-cells, it may exacerbate Kaposi’s sarcoma in HIV-positive patients. Rituximab-related Kaposi’s sarcomas have been previously reported in only two HIV-negative patients and were treated surgically. Here, we report on a Kaposi’s sarcoma that developed under rituximab treatment in a HIV-negative 55-year-old patient treated for follicular lymphoma. The lesion developed during the maintenance rituximab therapy at the rectal level with an aspect of apparent ulcerative colitis, without any cutaneous lesion. The premature stop of rituximab led to the complete regression of Kaposi’s sarcoma, without any additional specific treatment. To our knowledge, this is the third case of Kaposi’s sarcoma diagnosed under rituximab in a HIV-negative patient, the first one at the rectal level and the first one that completely regresses after stop of rituximab. This case raises awareness of iatrogenic Kaposi’s sarcoma in HIV-negative patients treated with rituximab, and further highlights the importance of immunosuppression in the pathophysiology of disease.

7 October 2025 in Cell Reports
Verified
Journal Article
Open access
EBEmilien BILLON
Emilien BILLON
CICaroline Imbert
Caroline Imbert
DBDamien Bruyat
Damien Bruyat
PGPierre Grassi
Pierre Grassi
LRLucie Robert
Lucie Robert
DODaniel Olive
Daniel Olive
Butyrophilins (BTNs) are emerging as novel druggable immune targets in oncology, promoting the activation of gamma delta (γδ) T cells against cancer cells. Therapies targeting BTN3A or BTN2A1 are under development, but their regulation is poorly understood. Here, we report that lymphocytes' BTN2A1 expression increases with CD3/CD28 stimulation, mediated by trogocytosis in the presence of activated myeloid cells. For instance, BTN2A1 can be acquired by the BTN2A1-knockout (BTN2A1KO) B cell line through trogocytosis when cultured with monocytes. In addition, cytotoxicity assays determine that BTN2A1-acquired normal or tumor cells exhibit higher sensitivity to Vγ9Vδ2 T cell lysis. Finally, we show that trogocytosis-mediated acquisition of BTN2A1 by circulating lymphocytes involves activated monocytes and is correlated with endometrial cancer stage in a cohort of 87 patients. This study provides new insights about the regulation and functions of BTN2A1 but also highlights the potential impact of trogocytosis in regulating the expression of immune checkpoints in normal and pathological conditions.

17 June 2026
Verified
Other
Open access
Laurent GorvelLaurent Gorvel
Laurent Gorvel
MPMarylou Panouillot
Marylou Panouillot
MRMarie-Sarah Rouvière
Marie-Sarah Rouvière
EBEmilien BILLON
Emilien BILLON
SFStéphane Fattori
Stéphane Fattori
DODaniel Olive
Daniel Olive
Cervical tumors are usually treated using surgery, chemotherapy, and radiotherapy and would benefit from immunotherapies. However, the immune microenvironment in cervical cancer remains poorly described. Tertiary lymphoid structures (TLS) were recently described as markers for better immunotherapy response and overall better prognosis in patients with cancer. We evaluated the cervical tumor immune microenvironment, specifically focusing on TLS, using combined high-throughput phenotyping, soluble factor concentration dosage in the tumor microenvironment, and spatial interaction analyses. We found that TLS presence was associated with a more inflammatory soluble microenvironment, with the presence of B cells as well as more activated macrophages and dendritic cells (DC). Furthermore, this myeloid cell activation was associated with the expression of immune checkpoints, such as PD-L1 and CD40, and the proximity of activated conventional type 2 DCs to CD8+ T cells, indicating better immune interactions and tumor control. Finally, we associated TLS presence, greater B-cell density, and activated DC density with improved progression-free survival, substantiating TLS presence as a potential prognostic marker. Our results provide evidence that TLS presence denotes cell activation and immunotherapy target expression.